Without ethanol, liver damage was not observed in GTA treatment groups, as assessed by serum alanine transaminase (ALT), hepatic triglyceride (TG) level, and hepatic steatosis (Fig. 4b–d, Supplementary Fig. 6), suggesting that ethanol-induced liver disease was not altered by GTA supplementation. The gene discussed is GPT; the disease is liver disorder.